Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.276 USD | +9.31% | +10.83% | -86.92% |
03-28 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
03-28 | ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1M 79.63M | Sales 2025 * | - | Capitalization | 2.79M 222M |
---|---|---|---|---|---|
Net income 2024 * | -12M -956M | Net income 2025 * | - | EV / Sales 2024 * | 2.79 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.18
x | P/E ratio 2025 * |
-
| Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.85% |
Latest transcript on ENDRA Life Sciences Inc.
1 day | +9.70% | ||
1 week | +10.83% | ||
Current month | -52.19% | ||
1 month | -31.21% | ||
3 months | -73.34% | ||
6 months | -70.18% | ||
Current year | -86.92% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 31/12/14 | |
Irina Pestrikova
DFI | Director of Finance/CFO | 38 | 17/06/21 |
Michael Thornton
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/12/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 30/06/13 | |
Alexander Tokman
BRD | Director/Board Member | 62 | 31/12/07 |
Michael Harsh
BRD | Director/Board Member | 69 | 31/12/14 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.2773 | +9.82% | 162 047 |
26/04/24 | 0.2525 | +4.12% | 11,104 |
25/04/24 | 0.2425 | -6.69% | 35,436 |
24/04/24 | 0.2599 | +2.16% | 42,059 |
23/04/24 | 0.2544 | +1.68% | 37,025 |
Delayed Quote Nasdaq, April 29, 2024 at 07:55 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.92% | 2.79M | |
+1.52% | 42.75B | |
+47.70% | 41.61B | |
+12.06% | 41.34B | |
-8.83% | 26.59B | |
+7.12% | 25.49B | |
-23.25% | 18.12B | |
+30.23% | 12.24B | |
-2.42% | 11.76B | |
+8.44% | 11B |
- Stock Market
- Equities
- NDRA Stock